A new study based on German long-COVID patients shows 68% experience the same symptoms in year 2 as in year 1 of the chronic ...

TEL AVIV, Israel (AP) — Hamas on Friday published the names of four hostages it said it would release the following day as ...

Bio, Inc. (THRD) has experienced a notable downturn, touching a 52-week low of $5.58. This latest price point reflects a significant retreat from more favorable positions over the past year, with the ...

In this Healio Video Perspective from Retina 2025, Peter K. Kaiser, MD, of Ocular Therapeutix, discusses positive data for ...

Abeona Therapeutics Inc.'s promising gene therapy for RDEB, potential FDA approval, undervalued stock, and key risks. Click ...

On Friday, however, Novo Nordisk announced top-line results in yet another trial. While the results don't initially sound as ...

A novel GLP-1 and amylin receptor agonist featured a safety profile similar to other incretin-based therapies and conferred a ...

MANCHESTER – A bold new vision for the Champions League was launched this season, meaning more games and more money for ...

Amycretin could give Novo a buzzy product in an newly competitive obesity market. It works similarly to existing GLP-1 ...

Joel Stanley, the founder and former CEO of Charlotte’s Web, is leading an effort to achieve approval from the FDA for a ...